Literature DB >> 23756710

Selective ablation of glucocorticoid receptor in mouse keratinocytes increases susceptibility to skin tumorigenesis.

Víctor Latorre1, Lisa M Sevilla1, Ana Sanchis1, Paloma Pérez2.   

Abstract

We recently demonstrated that mice lacking the epidermal glucocorticoid (GC) receptor (GR) (GR epidermal knockout (GR(EKO)) mice) have developmental defects and sensitivity to epidermal challenge in adulthood. We examined the susceptibility of GR(EKO) mice to skin chemical carcinogenesis. GR(EKO) mice treated with a low dose of 12-dimethylbenz(a) anthracene (DMBA) followed by phorbol 12-myristate 13-acetate (PMA) promotion exhibited earlier papilloma formation with higher incidence and multiplicity relative to control littermates (CO). Augmented proliferation and inflammation and defective differentiation of GR(EKO) keratinocytes contributed to the phenotype, likely through increased AKT and STAT3 (signal transducer and activator of transcription 3) activities. GR(EKO) tumors exhibited signs of early malignization, including delocalized expression of laminin A, dermal invasion of keratin 5 (K5)-positive cells, K13 expression, and focal loss of E-cadherin. Cultured GR(EKO) keratinocytes were spindle like, with loss of E-cadherin and upregulation of smooth muscle actin (SMA) and Snail, suggesting partial epithelial-mesenchymal transition. A high DMBA dose followed by PMA promotion generated sebaceous adenomas and melanocytic foci in GR(EKO) and CO. Importantly, the number, growth kinetics, and extent of both tumor types increased in GR(EKO) mice, suggesting that in addition to regulating tumorigenesis from epidermal lineages, GR in keratinocytes is important for cross-talk with other skin cells. Altogether, our data reinforce the importance of GR in the pathogenesis of skin cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756710     DOI: 10.1038/jid.2013.255

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Taurine and N-Bromotaurine in Topical Treatment of Psoriasis.

Authors:  Anthony M Kyriakopoulos; Markus Nagl; Ramesh C Gupta; Janusz Marcinkiewicz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Glucocorticoid Signaling in Health and Disease: Insights From Tissue-Specific GR Knockout Mice.

Authors:  Shannon Whirledge; Donald B DeFranco
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

3.  The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis.

Authors:  Rana Herro; Ricardo Da S Antunes; Amelia R Aguilera; Koji Tamada; Michael Croft
Journal:  J Invest Dermatol       Date:  2015-03-19       Impact factor: 8.551

4.  Defective glucocorticoid receptor signaling and keratinocyte-autonomous defects contribute to skin phenotype of mouse embryos lacking the Hsp90 co-chaperone p23.

Authors:  Marta Madon-Simon; Iwona Grad; Pilar Bayo; Paloma Pérez; Didier Picard
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

5.  Epidermal glucocorticoid and mineralocorticoid receptors act cooperatively to regulate epidermal development and counteract skin inflammation.

Authors:  Judit Bigas; Lisa M Sevilla; Elena Carceller; Julia Boix; Paloma Pérez
Journal:  Cell Death Dis       Date:  2018-05-22       Impact factor: 8.469

6.  GRowing an epidermal tumor.

Authors:  Wendy B Bollag; Carlos M Isales
Journal:  J Invest Dermatol       Date:  2013-12       Impact factor: 8.551

Review 7.  Roles of the Glucocorticoid and Mineralocorticoid Receptors in Skin Pathophysiology.

Authors:  Lisa M Sevilla; Paloma Pérez
Journal:  Int J Mol Sci       Date:  2018-06-29       Impact factor: 5.923

8.  Glucocorticoid-dependent transcription in skin requires epidermal expression of the glucocorticoid receptor and is modulated by the mineralocorticoid receptor.

Authors:  Lisa M Sevilla; Judit Bigas; Álvaro Chiner-Oms; Iñaki Comas; Vicente Sentandreu; Paloma Pérez
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.